Cutler Group LP Viking Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	BUY	$17.4 - $94.5 $48,719 - $264,600	2,800 New	2,800 $10,000
Q2 2023 Jul 18, 2023	SELL	$14.84 - $24.79 $310,156 - $518,111	-20,900 Reduced 69.44%	9,200 $114,000
Q1 2023 May 01, 2023	SELL	$8.08 - $17.33 $109,888 - $235,687	-13,600 Reduced 31.12%	30,100 $197,000
Q4 2022 Feb 07, 2023	BUY	$2.72 - $9.4 $103,904 - $359,080	38,200 Added 694.55%	43,700 $88,000
Q3 2022 Oct 25, 2022	SELL	$2.55 - $3.89 $1,275 - $1,945	-500 Reduced 8.33%	5,500 $0
Q2 2022 Aug 04, 2022	SELL	$2.11 - $3.15 $4,431 - $6,615	-2,100 Reduced 25.93%	6,000 $0
Q1 2022 Apr 14, 2022	BUY	$3.0 - $4.88 $11,700 - $19,032	3,900 Added 92.86%	8,100 $1,000
Q4 2019 Feb 06, 2020	BUY	$6.38 - $8.73 $14,036 - $19,206	2,200 Added 110.0%	4,200 $0
Q1 2019 May 10, 2019	SELL	$7.58 - $9.94 $8,338 - $10,934	-1,100 Reduced 35.48%	2,000 $2,000
Q4 2018 Feb 05, 2019	SELL	$7.16 - $16.21 $87,352 - $197,762	-12,200 Reduced 79.74%	3,100 $1,000
Q3 2018 Nov 07, 2018	SELL	$9.7 - $19.65 $140,650 - $284,925	-14,500 Reduced 48.66%	15,300 $46,000
Q2 2018 Aug 10, 2018	BUY	$3.88 - $12.74 $115,624 - $379,652	29,800 New	29,800 $29,000

464

65.3M

6.24M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.71B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.